These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 3525431)
1. Effects of short-term treatment with coenzyme A or sulodexide on plasma lipids in patients with hypertriglyceridemia (type IV) or mixed hyperlipemia (type IIb). Ghidini O; Zenari L; Guilarte N; Tessari R; Tomba A Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):390-6. PubMed ID: 3525431 [TBL] [Abstract][Full Text] [Related]
2. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype. Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592 [TBL] [Abstract][Full Text] [Related]
3. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs. Hutt V; Wechsler JG; Klör HU; Ditschuneit H Artery; 1980; 8(2):113-9. PubMed ID: 7458676 [TBL] [Abstract][Full Text] [Related]
4. [Long-term therapy of type II and type IV hyperlipoproteinemia using beclobrate]. Uglesić A; Ljachnicky N Schweiz Rundsch Med Prax; 1988 Jul; 77(27-28):755-61. PubMed ID: 3041534 [No Abstract] [Full Text] [Related]
5. Preliminary results of sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre trial. Crepaldi G; Fellin R; Calabrò A; Baiocchi MR; Rossi A; Lenzi S; Descovich GC; Delmonte G; Gaddi A; Ventura A Monogr Atheroscler; 1986; 14():215-21. PubMed ID: 3526129 [No Abstract] [Full Text] [Related]
6. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study. Goldberg AC; Schonfeld G; Feldman EB; Ginsberg HN; Hunninghake DB; Insull W; Knopp RH; Kwiterovich PO; Mellies MJ; Pickering J Clin Ther; 1989; 11(1):69-83. PubMed ID: 2655907 [TBL] [Abstract][Full Text] [Related]
7. Effect of gemfibrozil on serum lipid levels. Dahlén G; Gillnäs T; Børresen AL; Berg K; Ericson C Artery; 1980; 7(3):224-31. PubMed ID: 7008748 [TBL] [Abstract][Full Text] [Related]
8. [Use of etofyllinclofibrate (Duolip Forte) in combined hyperlipidemia]. Hrebícek J; Skottová N; Chmela Z; Hrbková M Cas Lek Cesk; 1995 Mar; 134(5):141-4. PubMed ID: 7728839 [TBL] [Abstract][Full Text] [Related]
9. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients. Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR Artery; 1985; 12(6):363-81. PubMed ID: 4051756 [TBL] [Abstract][Full Text] [Related]
10. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia]. Saitta A; Bonaiuto M; Lanzafame F; Mileto A; Pernice F; Cinquegrani M; Mazza G; Micali G; Pangallo A; Fodale P Clin Ter; 1988 Mar; 124(5):373-81. PubMed ID: 2974348 [No Abstract] [Full Text] [Related]
11. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate]. Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481 [TBL] [Abstract][Full Text] [Related]
12. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. Hutt V; Wechsler JG; Klör HU; Ditschuneit H Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558 [TBL] [Abstract][Full Text] [Related]
13. [Rapid effect of glucuronyl glucosamine glycan sulfate on the blood levels of HDL-cholesterol in vascular diseases]. Ferlito S; La Spina E; Cultrera E; Puleo F; Carrà G Arch Sci Med (Torino); 1982; 139(2):175-81. PubMed ID: 7138283 [TBL] [Abstract][Full Text] [Related]
14. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types]. Noseda G; Fragiacomo C; Weidmann P; Bachmann C Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660 [TBL] [Abstract][Full Text] [Related]
15. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835 [TBL] [Abstract][Full Text] [Related]
16. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia. Kehely A; MacMahon M; Barbir M; Wray R; Hunt BJ; Prescott RJ; Thompson GR QJM; 1995 Jun; 88(6):421-7. PubMed ID: 7648234 [TBL] [Abstract][Full Text] [Related]
17. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV. Lopez Rodriguez J; Martorell J Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061 [TBL] [Abstract][Full Text] [Related]
18. [The clinico-biochemical activity and tolerance of the hypolipidemic preparation lipanthyl]. Ol'binskaia LI; Vartanova OA; Aleksandrovskaia TN; Shaldaeva VV Ter Arkh; 1991; 63(8):61-4. PubMed ID: 1792621 [TBL] [Abstract][Full Text] [Related]
19. [Long-term effects of a glycosaminoglycan on plasma lipids]. Avogaro P; Bittolo-Bon G; Alessandrini P Clin Ter; 1981 Jul; 98(1):47-61. PubMed ID: 7249572 [No Abstract] [Full Text] [Related]
20. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]